Rhenium-186 -mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: In vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice

Japanese Journal of Cancer Research

Volumn 89, Issue 8, 1998, Pages 870-880

  Kinuya, Seigo ^a   Yokoyama, Kunihiko ^a   Tega, Harunobu ^a   Hiramatsu, Takashi ^a   Konishi, Shota ^a   Yamamoto, Wakako ^b   Shuke, Noriyuki ^b   Aburano, Tamio ^b   Watanabe, Naoto ^c   Takayama, Teruhiko ^a   Michigishi, Takatoshi ^a   Tonami, Norihisa ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Autoradiolysis; Biodistribution; Dosimetry; Monoclonal antibody; Rhenium 186

Indexed keywords

ASCORBIC ACID; CANCER ANTIBODY; IMMUNOGLOBULIN G; IODINE 131; MERTIATIDE TC 99M; MONOCLONAL ANTIBODY; PHENOL DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; THIOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON CANCER; CONTROLLED STUDY; DOSIMETRY; DRUG CONJUGATION; DRUG STABILITY; ESTERIFICATION; FEMALE; IMMUNOREACTIVITY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

EID: 0031687325     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00642.x     Document Type: Article

References (34)

1. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329, 459-465 (1993).
2. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D. C., Fisher, L. D. and Berstein, I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329, 1219-1224 (1993).
3. 125I radiolabeled T101 anti-CD5 monoclonal antibody. Nucl. Med. Biol., 17, 201-207 (1990).
4. Yokoyama, K., Carrasquillo, J. A., Chang, A. E., Colcher, D., Roselli, M., Sugarbaker, P., Sindelar, W., Reynolds, J. C., Perentesis, P., Gansow, O. A., Francis, B., Adams, R., Finn, R., Schlom, J. and Larson, S. M. Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. J. Nucl. Med., 30, 320-327 (1989).
5. Camera, L., Kinuya, S., Garmestani, K., Brechbiel, M. W., Wu, C., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H. and Carrasquillo, J. A. Comparative biodistribution of indium-and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). Eur. J. Nucl. Med., 21, 640-646 (1994).
6. Camera, L., Kinuya, S., Garmestani, K., Wu, C., Brechbiel, M. W., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H. and Carrasquillo, J. A. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J. Nucl. Med., 35, 882-889 (1994).
7. Deshpande, S. V., DeNardo, S. J., Kukis, D. L., Moi, M. K., McCall, M. J., DeNardo, G. L. and Meures, C. F. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J. Nucl. Med., 31, 473-479 (1990).
8. Sharkey, R. M. Motta-Hennessy, C., Pawlyk, D., Siegel, J. A. and Goldenberg, D. M. Biodistribution and radiation dose estimates for yttrium-and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res., 50, 2330-2336 (1990).
9. Kosmas, C., Maraveyas, A., Gooden, C. S., Snook, D. and Epenetos, A. A. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. J. Nucl. Med., 36, 746-753 (1995).
10. Behr, T. M., Becker, W. S., Bair, H.-J., Klein, M. W., Stühler, C. M., Cidlinsky, K. P., Wittekind, C. W., Scheele, J. R. and Wolf, F. G. Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J. Nucl. Med., 36, 430-441 (1995).
11. Oriuchi, N., Endo, K., Watanabe, N., Sugiyama, S., Asao, T., Takenoshita, S., Nagamachi, Y. and Baum, R. P. Semi-quantitative SPECT tumor uptake of technetium-99m-labeled anti-CEA monoclonal antibody in colorectal tumor. J. Nucl. Med., 36, 679-683 (1995).
12. Griffiths, G. L., Goldenberg, D. M., Knapp, F. F., Jr., Callahan, A. P. and Chang, C.-H. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. Cancer Res., 51, 4594-4602 (1991).
13. 99mTc-labeling of antibodies. Nucl. Med., 26, 7-12 (1987).
14. 4 chclate in vitro and HI vivo using tumor-bearing nude mice. Nucl. Med. Biol. 19, 205-212 (1992).
15. Visser, G. M. W., Gerretsen, M., Herscheid, J. D. M., Snow, G. B. and van Dongen, G. Labeling of monoclonal antibodies with rhenium-186 using MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J. Nucl. Med., 34, 1953-1963 (1993).
16. 186Re-labeled NR-LU-10 whole antibody in LS174T colonie tumor-bearing mice. Cancer Res., 50, 7973-7978 (1990).
17. Divgi, C. R., Scott, A. M., Dantis, L., Capitelli, P., Siler, K., Hilton, S., Finn, R. D., Kemeny, N., Kelsen, D., Kostakoglu, L., Schlom, J. and Larson, S. M. Phase I radioimmunotheraphy trial with iodine-131-CC49 in metastatic colon cancer. J. Nucl. Med., 36, 586-592 (1995).
18. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Ying, Z., Zhang, C.-H., Siegel, J. A. and Goldenberg, D. M. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J. Nucl. Med., 38, 409-418 (1997).
19. Wahl, R. L., Wissing, J., del Rosario, R. and Zasadny, K. R. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J. Nucl. Med., 31, 84-89 (1990).
20. Chakrabarti, M. C., Le, N., Paik, C. H., De Graff, W. G. and Carrasquillo, J. A. Prevention of radiolysis of monoclonal antibody during labeling. J. Nucl. Med., 37, 1384-1388 (1996).
21. Kotanagi, H., Takahashi, T., Masuko, T., Hashimoto, Y. and Koyama, K. A monoclonal antibody against human colon cancers. Tohoku J. Exp. Med., 148, 353-360 (1986).
22. Takahashi, T., Yamaguchi, T., Kitamura, K., Suzuyama, H., Honda, M., Yokota, T., Kotanagi, H., Takahashi, M. and Hashimoto, Y. Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy for colorectal carcinoma. Cancer. 61, 881-888 (1988).
23. Yamaoka, N., Yamaguchi, T., Otsuji, E., Kato, M., Kotani, T., Kitamura, K. and Takahashi, T. In vitro reactivity and in vivo biodistribution of the monoclonal antibody A7 using human gastric carcinoma cell lines. Br. J. Cancer, 70, 405-408 (1994).
24. 111In-labeled monoclonal antibody. Nucl. Med. Biol., 23, 137-140 (1996).
25. Lindmo, T., Boven, E., Cuttitta, C., Fedorko, J. and Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72, 77-89 (1984).
26. Dillman, L. T. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. MIRD Pamphlet-4. The Society of Nuclear Medicine, New York (1969).
27. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res., 53, 3524-3529 (1993).
28. 2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J. Nucl. Med., 31. 1035-1044 (1990).
29. Goldenberg, D. M. and Griffiths, G. L. Radioimmunotherapy of cancer: arming and missiles. J. Nucl. Med., 33, 1110-1112 (1992).
30. van Gog, F. B., Visser, G. W. M., Klok, R., van der Schos, R., Snow, G. B. and van Dongen, G. A. M. S. Monoclonal antibodies labeled with rhenium-186 using MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics. J. Nucl. Med., 37, 352-362 (1996).
31. 186Re]-labeled mouse and chimeric monoclonal antibody 323/Ab: a comparison of the efficacy in experimental human ovarian cancer. Nucl. Med. Biol., 25, 37-45 (1998).
32. Breitz, H. B., Weiden, P. L., Vanderheyden, J.-L., Appelbaum, J. W., Bjorn, M. J., Fer, M. F., Wolf, S. B., Ratliff, B. A., Seiler, C. A., Foisie, D. C., Fisher, D. R., Schroff, R. W., Fritzberg, A. R. and Abrams, P. G. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J. Nucl. Med., 33, 1099-1112 (1992).
33. 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res., 81, 676-681 (1991).
34. Kinuya, S., Yokoyama, K., Konishi, S., Hiramatsu, T., Tega, H., Michigishi, T. and Tonami, N. Induced hypertension and kinin degradation inhibition could benefit radioimmunotherapy in tumor-xenografted mice. J. Nucl. Med., 39, 106P (1998).